A prospective, open-label trial assessing dexamethasone pulse therapy in moderate to severe ulcerative colitis

Journal of Clinical Gastroenterology

Volumn 35, Issue 4, 2002, Pages 328-331

  Sood, Ajit ^a,b   Midha, Vandana ^a   Sood, Neena ^a   Awasthi, Gurcharan ^a  

^a DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^b Opp New DMC and H   (India)

Author keywords

Dexamethasone pulse therapy; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; SALAZOSULFAPYRIDINE; SAZO EN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0036785418     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200210000-00009     Document Type: Article

References (29)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955;1041.
2. Meyers S, Sachar DB, Goldberg JD, et al. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. Gastroenterology 1983;85:351-7.
3. Marion JF, Present DH. The modem medical management of acute, severe ulcerative colitis. Eur J Gastroenterol Hepatol 1997;9:831-5.
4. Engel T, Dirksen A, Frolund L, et al. Methylprednisolone pulse therapy in acute severe asthma: a randomized, double-blind study. Allergy 1990;45:224-30.
5. Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 1999;58:363-8.
6. Lashina NI, Solov' ev SK, Balabanova RM. Treatment with megadose of Dexaven (dexamethasone) versus methylprednisolone (6-methylprednisolone) of patients with rheumatoid arthritis. Ter Arkh 2000;72:28-31.
7. Mitsuru S, Mitsuo O, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971-6.
8. Truelove SC, Jewell DP. Intensive intravenous regime for severe attacks of ulcerative colitis. Lancet 1974;1(7866):1067-70.
9. Kountz SL, Cohn R. Initial treatment of renal allografts with large intrarenal doses of immunosuppressive drugs. Lancet 1969;1:338-40.
10. Johnson RB, Lazarus GS. Pulse therapy: therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol 1982;118:76-84.
11. Dasgupta B, Dolan AL, Panayi GS, et al. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998;37:189-95.
12. Choy EH, Kingsley GH, Corkill MM, et al. Intramuscular methylprednisolone during the induction phase of chrysotherapy. Br J Rheumatol 1993;32:734-9.
13. Feraz MB, Visioni RA, Oliveira LM, et al. Intravenous methylprednisolone therapy in rheumatoid arthritis. Scand J Rheumatol 1992;21:260-1.
14. Hayball PJ, Cosh DG, Ahern MJ, et al. High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Eur J Clin Pharmacol 1992;42:85-8.
15. Iglehart ID, Sultan JD, Bendor JC, et al. Intravenous pulsed steroids in rheumatoid arthritis: a comparative dose study. J Rheumatol 1990;17:159-62.
16. Radia M, Furst DE. Comparison of three methylprednisolone regimens in the treatment of rheumatoid arthritis. J Rheumatol 1988;15:242-6.
17. Edward JCW, Snaith ML, Isenberg DA. A double blind controlled trial of methylpredinsolone infusion in systemic lupus erythematosus using individualized outcome assessment. Ann Rheum Dis 1987;46:773-6.
18. Alam SM, Kyriakides T, Lawden M, et al. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-20.
19. Iglehart IW 3rd, Sulton JD, Bender JC, et al. Intravenous pulsed steroids in rheumatoid arthritis: a comparative dose study. J Rheumatol 1990;17:159-62.
20. Rosenberg W, Ireland A, Jewell D. High dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990;12:40-1.
21. Hari P, Srivastava RN. Pulse corticosteroid therapy with methylprednisolone or dexamethasone. Indian Pediatr 1998;65:557-60.
22. Roujeau JC. Pulse glucocorticoid therapy: the 'big shot' revisited. Arch Dermatol 1996;132:1499-502.
23. Pasricha JS. Curative effect of dexamethasone: cyclophosphamide pulse therapy for treatment of pemphigus vulgaris. Int J Dermatol 1992;31:875-7.
24. Kaur S, Kanwar AJ. Dexamethasone cyclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990;29:371-4.
25. Pasricha JS, Gupta R. Pulse therapy with dexamethasone in Reiter's disease. Indian J Dermatol Venereol Leprol 1982;48:358-61.
26. Pasricha JS. Reversal of systemic aclerosis with dexamethasone pulse therapy. Indian J Dermatol Venereol Leprol 1991;57:225-8.
27. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304-15.
28. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-90.
29. Farell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279-88.